ASPEN PHARMACARE HOLDINGS LIMITED AND ITS SUBSIDIARIES
Registration number: 1985/002935/06
JSE Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
("Aspen" or "the Group")

Condensed Group financial results for the year ended 30 June 2024 and cash dividend declaration

COMMENTARY

Over the reporting period, Aspen has successfully delivered on several of its important strategic objectives including:

- Delivering its highest ever 6-month normalised EBITDA in H2 2024, growing 17% over H1 2024. This is a significant step in shaping the Group's sustainable growth path;
- Robust cash generation from earnings, reflected in the return to a cash conversion ratio in excess of 100% and underpinned by a sustainably lower working capital investment;
- The Commercial Pharmaceuticals business having absorbed the sharp price decreases incurred in China under the national volume based procurement ("VBP") programme. Together with Russia CIS, sales were impacted by circa R2 billion. Resolving this negative overhang, coupled with successfully concluding regional acquisitions in China and Latin America has not only derisked the base business but also puts it firmly on a growth trajectory;
- The introduction of a new operating model for the Heparin business which has resulted in an unwind of R2,9 billion in associated inventory;
- Utilising existing capacity and successfully transferring manufacturing contracts into its facilities, is core to the future growth strategy. The contribution from these contracts in FY 2024 exceeded the guidance provided of R500 million; and
- Its pursuit of manufacturing and commercial opportunities to enter the rapidly growing GLP-1 market for breakthrough products in the treatment of diabetes and obesity which has advanced positively. Some GLP-1 patents have lapsed in specific markets with further patent expirations anticipated starting 2026.

GROUP FINANCIAL RESULTS HIGHLIGHTS

Key financial indicators[1]	**Reported June 2024 R'million**	Reported June 2023 R'million	Change at reported rates %	Change at CER[2] %
Revenue	**44 706**	40 709	10	5
Gross profit	**19 454**	18 934	3	(1)
Operating profit	**6 998**	7 822	(11)	(13)
Normalised EBITDA[3]	**11 255**	11 100	1	(3)
Headline earnings per share (cents)	**1 356,6**	1 405,4	(3)	(7)
Normalised headline earnings per share (cents)[4]	**1 492,1**	1 498,5	(0)	(4)
Earnings per share (cents)	**991,4**	1 176,9	(16)	(18)
Dividend per share[5]	**359**	342	5	–

[1] *The Group assesses its operational performance using constant exchange rates ("CER"). The table above compares performance to the prior comparable period at reported exchange rates and at CER.*
[2] *The CER % change is based upon the performance for the year ended 30 June 2023 recalculated using the average exchange rates for the year ended 30 June 2024.*
[3] *Operating profit before depreciation and amortisation adjusted for specific non-trading items as defined in the Group's accounting policy.*
[4] *Normalised headline earnings per share ("NHEPS") is headline earnings per share ("HEPS") adjusted for specific non-trading items as defined in the Group's accounting policy.*
[5] *Dividend declared on 2 September 2024, to be paid on 23 September 2024 (2023: Declared on 29 August 2023 and paid 26 September 2023).*

GROUP PERFORMANCE

H2 2024 was the start of Aspen's journey to both realising the tangible benefits from sterile manufacturing investments and the delivery of a predictable, resilient, growing Commercial Pharmaceuticals business that has managed and absorbed the VBP risks in China. In FY 2024 the Group has achieved a record H2 normalised EBITDA of R6 061 million up 17% on H1 2024. The higher than anticipated negative impact of VBP resulted in Aspen falling short of its targeted mid-single digit growth in EBITDA.

Group Revenue for the reporting period was up 10% led by Manufacturing growing by 25% and Commercial Pharmaceuticals increasing by 4%. Gross Profit grew 3% diluted by an increased Manufacturing sales mix with the primary driver being the liquidation of Heparin inventory of R2,9 billion. Normalised EBITDA of R11 255 million was up 1%.

Net financing costs of R1 232 million (R1 284 million adjusted for capital raising fees on transactions of R52 million) remained flat compared to the prior financial year. Increased net interest costs, fueled by higher rates and increased net debt levels, were offset by lower foreign exchange losses resulting from reduced volatility in emerging market currencies relative to the Euro. Financing costs in FY 2025 will continue to be influenced by the interest rate cycle and currency volatility. NHEPS of 1 492 cents ended marginally below FY 2023. HEPS declined by 3% and earnings per share ended 16% lower affected by higher acquisition related transaction costs and the impairment of VBP impacted intangible assets respectively.

Operating cash flow per share of 1 401 cents grew 13%, supported by an improved operating cash conversion rate of 103% (FY 2023: 88%). This exceeded our internal benchmark of 100%. Solid operating cash flows, even after partial funding of the Latin American product portfolio acquisition of R2,1 billion, coupled with the benefit of reducing the Group's investment in Heparin inventory by R2,9 billion were the key catalysts in this positive shift. Net debt increased from R22,2 billion in June 2023 to R26,9 billion in June 2024 with net acquisitions totalling R7,7 billion being key to the rise. The leverage ratio ended at 2,3x comfortably within the Group's targeted range.

SEGMENTAL PERFORMANCE

Commercial Pharmaceuticals

Commercial Pharmaceuticals revenue grew by 4% to R30 570 million with the growth in Prescription and OTC more than offsetting the decline in Injectables revenue. Gross profit margins were marginally lower at 59,4% (FY 2023: 60,0%) after absorbing the impact of VBP in China.

Prescription

Prescription Brands enjoyed double digit growth of 15%, recording revenue of R11 380 million. The revenue growth was underpinned by solid organic growth in its largest region, Africa Middle East, and organic and acquisitive growth in the Americas which is now the second largest region.

Gross profit percentage was up at 60.9% (FY 2023: 60,7%) with favourable sales mix more than offsetting the impact of the regulated price cuts in Australia.

OTC

OTC, the second largest segment in Commercial Pharmaceuticals, grew revenue by 7% to R9 706 million with all regions reporting solid growth. Gross profit percentage of 58,7% remained in line with the prior year of 58,6%.

Injectables

Injectables was impacted by the more severe than expected outcome of VBP in China on Fraxiparine and Diprivan. Growth in Africa Middle East and the Americas (most notably Brazil) partly mitigated the overall segment sales reduction which recorded a revenue decline of 9% to R9 484 million.

Gross profit percentage declined to 58,2% (FY 2023: 60,6%) influenced by the impact of VBP, partly offset by cost of goods savings from the continuing insourcing of sterile production.

Manufacturing

Manufacturing revenue grew significantly, increasing 25% partly aided by exchange rate tailwinds. FDF revenue growth accelerated from 10% in H1 2024 to 33% at year-end, supported by an increased contribution in H2 2024 from third-party contracts for sterile manufacturing. Heparin revenue growth of R1 469 million over the comparable period was largely due to the transition to toll manufacture. API sales were up 2%, following a rebound in H1 2024.

Gross profit of R1 307 million was 2% ahead of FY 2023. The gross profit percentage ended lower at 9,2% (FY 2023: 11,4%) influenced by the increased sales mix of Heparin and the non-recurrence of the grant funding enjoyed in the prior year.

PROSPECTS

The Group has achieved a solid set of results for the year ended 30 June 2024 even after absorbing the more severe impact of VBP in China. The 17% growth in normalised EBITDA in H2 2024 compared to H1 2024 sets a firm foundation in building momentum for anticipated strong growth in FY 2025.

The Commercial Pharmaceuticals business has been derisked and is well poised for future growth. We anticipate Commercial Pharmaceuticals will achieve double digit CER revenue growth in FY 2025 supported by underlying growth in all three business segments and underpinned by organic growth accompanied by annualised growth from recent portfolio acquisitions.

For Manufacturing we expect FDF, supported by an increased sterile capacity fill contribution, to be the main contributor to CER EBITDA growth in FY 2025. Over the period FY 2025 to FY 2026 (compared to FY 2024) we estimate CER EBITDA to increase incrementally by R2 450 million from these initiatives. This value growth is consistent with previous guidance, but the realisation may vary between the two financial years, dependant on the timing of the South African regulatory approvals.

Supporting our capacity fill and commercial initiatives, Aspen has also secured a commercial licence for the intellectual property necessary to commercialise GLP-1s post the expiry of the originator product patents. In addition, Aspen will be the exclusive global supplier of these products to the licensor. This exciting opportunity could benefit Aspen from calendar year 2026 onwards and consequently also be additive to the capacity fill contributions for FY 2026.

Finance costs will continue to be influenced by the interest rate cycle. We are expecting an increase in net interest costs driven by the residual impact of current higher interest rates being carried forward to FY 2025. We expect the effective tax rate to increase in FY 2025 as the profit contribution from sterile manufacturing increases. Lower working capital investment and strong operating cash flows should assist us in achieving an operating cash conversion rate greater than our target of 100%.

Any forecast information in the above-mentioned paragraphs has not been reviewed or reported on by the Group's auditors and is the responsibility of the directors. The full announcement has been released on SENS and is available on Aspen's website. Any investment decision must be based on the information contained in the full announcement.

DECLARATION OF DIVIDEND

The Board has declared a gross dividend of 359 cents per ordinary share (2023: 342 cents per share) (or 287,2 cents net of a 20% dividend withholding tax, where this maximum rate of tax applies) which represents an increase of 5% in gross dividend per share and will be paid from income reserves.

Shareholders should seek their own advice on the tax consequences associated with the dividend and are particularly encouraged to ensure their records are up to date with Aspen so that the correct withholding tax rate is applied to their dividend. The Company income tax number is 9325178714. The issued share capital of the Company is 446 252 332 ordinary shares. Future distributions will continue to be decided on a year-to-year basis. In compliance with IAS 10 – *Events After Balance Sheet Date*, the dividend will be accounted for in the financial statements in the year ended 30 June 2024.

Last day to trade cum dividend	Tuesday, 17 September 2024
Shares commence trading ex-dividend	Wednesday, 18 September 2024
Record date	Friday, 20 September 2024
Payment date	Monday, 23 September 2024

Share certificates may not be dematerialised or rematerialised between Wednesday, 18 September 2024 and Friday, 20 September 2024.

For and on behalf of the Board

KD Dlamini	**SB Saad**	**SM Capazorio**
Chair	Group Chief Executive	Group Chief Financial Officer

GROUP STATEMENT OF FINANCIAL POSITION

at 30 June	Note[1]	Reviewed 2024 R'million	Audited 2023 R'million
ASSETS			
Non-current assets			
Intangible assets		**66 352**	63 104
Property, plant and equipment		**19 946**	18 495
Right-of-use assets		**563**	402
Goodwill		**5 462**	5 596
Deferred tax assets		**1 794**	1 579
Contingent environmental indemnification assets		**298**	343
Other non-current receivables		**654**	265
Total non-current assets		**95 069**	89 784
Current assets			
Inventories		**18 002**	19 606
Receivables and other current assets		**12 664**	13 053
Current tax assets		**1 083**	929
Cash and cash equivalents		**12 337**	10 912
Total current assets		**44 086**	44 500
Total assets		**139 155**	134 284
SHAREHOLDERS' EQUITY			
Reserves		**83 208**	84 567
Share capital (net of treasury shares)		**1 653**	1 669
Total shareholders' equity		**84 861**	86 236
LIABILITIES			
Non-current liabilities			
Borrowings[2]		**25 141**	21 375
Other non-current liabilities	A	**2 192**	497
Deferred tax liabilities		**1 582**	1 995
Contingent environmental indemnification liabilities		**298**	343
Retirement and other employee benefits		**701**	690
Total non-current liabilities		**29 914**	24 900
Current liabilities			
Borrowings[3]		**11 314**	7 907
Trade and other payables		**10 347**	10 180
Other current liabilities	A	**1 928**	4 161
Current tax liabilities		**791**	900
Total current liabilities		**24 380**	23 148
Total liabilities		**54 294**	48 048
Total equity and liabilities		**139 155**	134 284

[1] *Refer to notes in Supplementary Information.*
[2] *Borrowings have increased from last year mainly as a result of acquisitions and partly due to the payment of the first of three installments of the MSD loan.*
[3] *Current borrowings includes bank overdrafts.*

GROUP STATEMENT OF COMPREHENSIVE INCOME

for the year ended 30 June	Note[1]	Change %	Reviewed 2024 R'million	Audited 2023 R'million
Revenue		10	**44 706**	40 709
Cost of sales			**(25 252)**	(21 775)
Gross profit		3	**19 454**	18 934
Selling and distribution expenses			**(6 481)**	(5 799)
Administrative expenses			**(3 657)**	(3 627)
Other operating income			**1 543**	696
Other operating expenses			**(3 861)**	(2 382)
Operating profit	B	(11)	**6 998**	7 822
Investment income	C		**1 059**	529
Financing costs	D		**(2 343)**	(1 796)
Profit before tax		(13)	**5 714**	6 555
Tax			**(1 310)**	(1 327)
Profit for the year		(16)	**4 404**	5 228
OTHER COMPREHENSIVE INCOME, NET OF TAX[2]				
Currency translation (losses)/gains	E		**(4 274)**	11 563
Remeasurement of retirement and other employee benefits			**7**	20
Total comprehensive income			**137**	16 811
Weighted average number of shares in issue ('million)			**444,2**	444,2
Diluted weighted average number of shares in issue ('million)			**444,2**	444,2
EARNINGS PER SHARE				
Basic and diluted earnings per share (cents)		(16)	**991,4**	1 176,9

[1] *Refer to notes in Supplementary Information.*
[2] *Remeasurements of retirement and other employee benefit obligations are not reclassified to profit and loss. All other items in other comprehensive income are reclassified to profit or loss.*

GROUP STATEMENT OF CHANGES IN EQUITY

	Share capital (net of treasury shares) R'million	Reserves R'million	Total R'million
BALANCE AT 1 JULY 2022	1 784	69 158	70 942
Total comprehensive income	–	16 811	16 811
Profit for the year	–	5 228	5 228
Other comprehensive income	–	11 583	11 583
Dividends paid	–	(1 455)	(1 455)
Treasury shares purchased	(136)	–	(136)
Deferred incentive bonus shares exercised	21	(21)	–
Share-based payment expense	–	74	74
BALANCE AT 30 JUNE 2023	**1 669**	**84 567**	**86 236**
Total comprehensive income	**–**	**137**	**137**
Profit for the year	**–**	**4 404**	**4 404**
Other comprehensive loss	**–**	**(4 267)**	**(4 267)**
Dividends paid	**–**	**(1 525)**	**(1 525)**
Treasury shares purchased	**(56)**	**–**	**(56)**
Deferred incentive bonus shares exercised	**40**	**(40)**	**–**
Share-based payment expense	**–**	**69**	**69**
BALANCE AT 30 JUNE 2024	**1 653**	**83 208**	**84 861**

DISTRIBUTION TO SHAREHOLDERS

The dividend paid to shareholders of 342 cents (2023: 326 cents) per share relates to the dividend declared on 29 August 2023 and paid on 26 September 2023 (2023: declared on 30 August 2022 and paid on 26 September 2022).

GROUP STATEMENT OF CASH FLOWS

for the year ended 30 June	Note[1]	Change %	Reviewed 2024 R'million	Audited 2023 R'million
CASH FLOWS FROM OPERATING ACTIVITIES				
Cash operating profit	F		**9 967**	11 300
Changes in working capital			**(242)**	(3 358)
Cash generated from operations			**9 725**	7 942
Financing costs paid			**(2 410)**	(1 337)
Investment income received			**1 059**	529
Tax paid			**(2 149)**	(1 614)
Cash generated from operating activities			**6 225**	5 520
CASH FLOWS FROM INVESTING ACTIVITIES				
Capital expenditure – property, plant and equipment	H		**(3 117)**	(2 230)
Proceeds received from disposal of property, plant and equipment			**13**	5
Capital expenditure – intangible assets	H		**(2 418)**	(951)
Proceeds received from disposal of intangible assets			**2**	4
Contractual prepayments			**(595)**	–
Proceeds received from disposal of other non-current assets			**61**	17
Payment of deferred, fixed and contingent consideration relating to prior year business transactions	I		**(158)**	(309)
Acquisition of a portfolio of products in Latin America	J		**(3 229)**	–
Acquisition of a subsidiary and business in China net of cash acquired	K		**(963)**	–
Proceeds from disposal of European Anaesthetic brands	L		**936**	–
Insurance compensation on assets			**–**	43
Cash utilised in investing activities			**(9 468)**	(3 421)
CASH FLOWS FROM FINANCING ACTIVITIES				
Proceeds from borrowings[2]			**13 988**	7 939
Repayment of borrowings			**(7 571)**	(6 585)
Repayment of lease liabilities			**(201)**	(183)
Repayment of MSD loan	A		**(1 012)**	–
Purchase of treasury shares			**(56)**	(136)
Dividends paid			**(1 525)**	(1 455)
Cash generated from/(utilised in) financing activities			**3 623**	(420)
Movement in cash and cash equivalents before currency translation movements			**380**	1 679
Currency translation movements			**(653)**	843
Movement in cash and cash equivalents			**(273)**	2 522
Cash and cash equivalents at the beginning of the year			**7 493**	4 971
Cash and cash equivalents at the end of the year[3]			**7 220**	7 493
Operating cash flow per share (cents)	G	13	**1 401,4**	1 242,6
RECONCILIATION OF CASH AND CASH EQUIVALENTS				
Cash and cash equivalents per the statement of financial position			**12 337**	10 912
Less: bank overdrafts			**(5 117)**	(3 419)
			7 220	7 493

[1] *Refer to notes in Supplementary Information.*
[2] *Borrowings have increased from last year mainly as a result of acquisitions and partly due to the payment of the first of three installments of the MSD loan.*
[3] *For the purposes of the statement of cash flows, cash and cash equivalents comprise cash-on-hand plus deposits held on call with banks less bank overdrafts.*

GROUP SUPPLEMENTARY INFORMATION
GROUP STATEMENT OF HEADLINE EARNINGS

for the year ended 30 June	Change %	Reviewed 2024 R'million	Audited 2023 R'million
HEADLINE EARNINGS			
Reconciliation of headline earnings			
Profit attributable to equity holders of the parent	(16)	**4 404**	5 228
Adjusted for			
– Net impairment of property, plant and equipment (net of tax)		**81**	3
– Net impairment of intangible assets (net of tax)		**1 385**	998
– Loss on the sale of tangible and intangible assets (net of tax)		**11**	44
– Net impairment of goodwill (net of tax)		**145**	–
– Insurance compensation on assets (net of tax)[1]		**–**	(30)
	(3)	**6 026**	6 243
HEADLINE EARNINGS PER SHARE			
Headline earnings and diluted headline earnings per share (cents)	(3)	**1 356,6**	1 405,4
NORMALISED HEADLINE EARNINGS			
Reconciliation of normalised headline earnings			
Headline earnings	(3)	**6 026**	6 243
Adjusted for			
– Restructuring costs (net of tax)		**217**	210
– Transaction costs (net of tax)[2]		**385**	204
	(0)	**6 628**	6 657
NORMALISED HEADLINE EARNINGS PER SHARE			
Normalised headline and diluted headline earnings per share (cents)	(0)	**1 492,1**	1 498,5
NORMALISED EBITDA			
Reconciliation of normalised EBITDA[3]			
Operating profit		**6 998**	7 822
Headline earnings adjustments			
– Net impairment of assets		**1 667**	1 064
– Insurance compensation on assets[1]		**–**	(43)
– Loss on sale of assets		**34**	1
Normalised earnings adjustments			
– Restructuring costs		**227**	278
– Transaction costs		**356**	190
EBITDA adjustments			
– Depreciation		**1 390**	1 247
– Amortisation		**583**	541
	1	**11 255**	11 100

[1] *Relates to insurance compensation on damaged property, plant and equipment following the fire at Alphamed Formulations Pvt Limited's formulation site.*

[2] *Included in transaction costs is capital raising fees (net of tax) of R40 million (2023: R36 million).*

[3] *Normalised EBITDA represents operating profit before depreciation and amortisation adjusted for specific non-trading items as defined in the Group's accounting policy.*

GROUP SUPPLEMENTARY INFORMATION continued

GROUP SEGMENTAL ANALYSIS

Reviewed year ended 30 June 2024

	Prescription R'million	OTC R'million	Injectables R'million	Total Commercial Pharmaceuticals R'million	Manufacturing R'million	Total R'million
Revenue	**11 380**	**9 706**	**9 484**	**30 570**	**14 136**	**44 706**
Cost of sales	**(4 447)**	**(4 012)**	**(3 964)**	**(12 423)**	**(12 829)**	**(25 252)**
Gross profit	**6 933**	**5 694**	**5 520**	**18 147**	**1 307**	**19 454**
Selling and distribution expenses						**(6 481)**
Administrative expenses						**(3 657)**
Net other operating income						**549**
Depreciation						**1 390**
Normalised EBITDA[1]						**11 255**
Gross profit (%)	**60,9**	**58,7**	**58,2**	**59,4**	**9,2**	**43,5**
Selling and distribution expenses (%)						**14,5**
Administrative expenses (%)						**8,2**
Normalised EBITDA (%)						**25,2**

Audited restated[2] year ended 30 June 2023

	Prescription R'million	OTC R'million	Injectables R'million	Total Commercial Pharmaceuticals R'million	Manufacturing R'million	Total R'million
Revenue	9 921	9 106	10 385	29 412	11 297	40 709
Cost of sales	(3 901)	(3 774)	(4 090)	(11 765)	(10 010)	(21 775)
Gross profit	6 020	5 332	6 295	17 647	1 287	18 934
Selling and distribution expenses						(5 799)
Administrative expenses						(3 627)
Net other operating income						345
Depreciation						1 247
Normalised EBITDA[1]						11 100
Gross profit (%)	60,7	58,6	60,6	60,0	11,4	46,5
Selling and distribution expenses (%)						14,2
Administrative expenses (%)						8,9
Normalised EBITDA (%)						27,3

Change

	Prescription %	OTC %	Injectables %	Total Commercial Pharmaceuticals %	Manufacturing %	Total %
Revenue	**15**	**7**	**(9)**	**4**	**25**	**10**
Cost of sales	**14**	**6**	**(3)**	**6**	**28**	**16**
Gross profit	**15**	**7**	**(12)**	**3**	**2**	**3**
Selling and distribution expenses						**12**
Administrative expenses						**1**
Net other operating income						**59**
Depreciation						**11**
Normalised EBITDA[1]						**1**

[1] *Normalised EBITDA represents operating profit before depreciation and amortisation adjusted for specific non-trading items as defined in the Group's accounting policy.*

[2] *Refer to Basis of Accounting for restatement as a result of segmental classifications.*

GROUP SUPPLEMENTARY INFORMATION continued

GROUP REVENUE SEGMENTAL ANALYSIS

for the year ended 30 June	Reviewed 2024 R'million	Audited restated[2] 2023 R'million	Change %
COMMERCIAL PHARMACEUTICALS BY CUSTOMER GEOGRAPHY	**30 570**	29 412	4
Africa Middle East	**9 021**	8 154	11
Americas	**6 677**	5 079	31
Australasia	**5 904**	5 827	1
Europe CIS	**4 868**	4 847	0
Asia	**4 100**	5 505	(26)
MANUFACTURING REVENUE BY GEOGRAPHY OF MANUFACTURE			
Finished dose form	**5 262**	3 970	33
Europe CIS	**4 131**	2 655	56
Australasia	**781**	727	7
Africa Middle East	**216**	454	(52)
Asia	**100**	115	(13)
Americas	**34**	19	79
Active pharmaceutical ingredients	**5 102**	5 024	2
Europe CIS	**4 832**	4 832	0
Africa Middle East	**270**	192	41
Heparin	**3 772**	2 303	64
Europe CIS	**3 772**	2 303	64
Total Manufacturing revenue	**14 136**	11 297	25
TOTAL REVENUE	**44 706**	40 709	10
SUMMARY OF REGIONS			
Europe CIS	**17 603**	14 637	20
Africa Middle East	**9 507**	8 800	8
Americas	**6 711**	5 098	32
Australasia	**6 685**	6 554	2
Asia	**4 200**	5 620	(25)
TOTAL REVENUE	**44 706**	40 709	10

[2] *Refer to Basis of Accounting for restatement as a result of segmental classifications.*

COMMERCIAL PHARMACEUTICALS THERAPEUTIC AREA ANALYSIS

	Reviewed year ended 30 June 2024			
	Prescription R'million	OTC R'million	Injectables R'million	Total R'million
BY CUSTOMER GEOGRAPHY				
Africa Middle East	**4 242**	**3 561**	**1 218**	**9 021**
Americas	**2 832**	**1 450**	**2 395**	**6 677**
Australasia	**2 618**	**2 430**	**856**	**5 904**
Europe CIS	**991**	**1 974**	**1 903**	**4 868**
Asia	**697**	**291**	**3 112**	**4 100**
Total Commercial Pharmaceuticals	**11 380**	**9 706**	**9 484**	**30 570**

	Audited restated[1] year ended 30 June 2023			
	Prescription R'million	OTC R'million	Injectables R'million	Total R'million
BY CUSTOMER GEOGRAPHY				
Africa Middle East	3 876	3 501	777	8 154
Americas	1 801	1 323	1 955	5 079
Australasia	2 713	2 278	836	5 827
Europe CIS	989	1 742	2 116	4 847
Asia	542	262	4 701	5 505
Total Commercial Pharmaceuticals	9 921	9 106	10 385	29 412

	Change			
	Prescription %	OTC %	Injectables %	Total %
BY CUSTOMER GEOGRAPHY				
Africa Middle East	9	2	57	11
Americas	57	10	23	31
Australasia	(4)	7	2	1
Europe CIS	0	13	(10)	0
Asia	29	11	(34)	(26)
Total Commercial Pharmaceuticals	15	7	(9)	4

[1] *Refer to Basis of Accounting for restatement as a result of segmental classifications.*

NOTES

	Note	Reviewed 30 June 2024 R'million	Audited 30 June 2023 R'million
A. OTHER NON-CURRENT AND CURRENT LIABILITIES			

Included in current liabilities of the prior year was an interest-free loan owing by Aspen Oss to Merck Sharpe and Dohme ("MSD") for EUR188 million which was required to be repaid in full on or before October 2023. In the current year, Aspen reached an agreement with MSD to extend the loan repayment terms and repay EUR50 million of the outstanding amount on 30 September 2023 with the balance being payable in two equal instalments of EUR69 million on or before October 2024 and 1 October 2025, respectively. The original loan incurred notional interest up to 30 September 2023. The extended loan attracts interest from 1 October 2023 at a fixed market-related rate which is lower than the effective notional interest rate. During the current year R1 012 million (EUR50 million) was repaid.

	Note	Reviewed 30 June 2024 R'million	Audited 30 June 2023 R'million
B. OPERATING PROFIT HAS BEEN ARRIVED AT AFTER CHARGING/ (CREDITING)			
Depreciation of tangible assets		**1 390**	1 247
Amortisation of intangible assets		**583**	541
Net impairment of tangible and intangible assets		**1 667**	1 064
Impairment of tangible assets		**84**	4
Impairment of intangible assets	M	**2 415**	1 359
Impairment reversal of intangible assets	M	**(977)**	(299)
Impairment of goodwill	M	**145**	–
Loss on the sale of tangible and intangible assets		**34**	1
Restructuring costs		**227**	278
Transaction costs		**356**	190
Insurance compensation on assets		**–**	(43)
C. INVESTMENT INCOME			
Interest received		**1 059**	529
D. FINANCING COSTS			
Interest paid		**(2 166)**	(1 120)
Capital raising fees – transactions		**(52)**	(38)
Net losses on financial instruments		**(64)**	(434)
Net foreign exchange losses		**(49)**	(688)
Fair value (losses)/gains on financial instruments		**(15)**	254
Notional interest on financial instruments		**(61)**	(204)
		(2 343)	(1 796)

	Reviewed 30 June 2024 R'million	Audited 30 June 2023 R'million
E. CURRENCY TRANSLATION (LOSSES)/GAINS		
Currency translation (losses)/gains on the translation of the offshore businesses are as a result of the difference between the weighted average exchange rate used for trading results and the opening and closing exchange rates applied in the statement of financial position. For the year the stronger closing Rand translation rate has decreased the Group's net asset value.	**(4 274)**	11 563
Average rates		
Euro	**20,233**	18,613
Australian Dollar	**12,263**	11,948
Chinese Yuan Renminbi	**2,593**	2,555
US Dollar	**18,707**	17,758
Mexican Peso	**1,089**	0,940
Brazilian Real	**3,732**	3,455
British Pound Sterling	**23,556**	21,395
Canadian Dollar	**13,809**	13,257
Russian Ruble	**0,203**	0,260
Closing rates		
Euro	**19,468**	20,568
Australian Dollar	**12,122**	12,549
Chinese Yuan Renminbi	**2,502**	2,597
US Dollar	**18,185**	18,839
Mexican Peso	**0,997**	1,100
Brazilian Real	**3,271**	3,909
British Pound Sterling	**22,996**	23,941
Canadian Dollar	**13,292**	14,232
Russian Ruble	**0,212**	0,211
F. CASH OPERATING PROFIT		
Operating profit	**6 998**	7 822
Non-cash items	**2 969**	3 478
	9 967	11 300
G. CASH CONVERSION RATE		
Cash generated from operating activities	**6 225**	5 520
Operating cash flow per share (cents)[1]	**1 401,4**	1 242,6
Headline earnings per share (cents)	**1 356,3**	1 405,4
Cash conversion rate[2]	**103%**	88%
H. CAPITAL EXPENDITURE		
Incurred	**5 535**	3 181
– Property, plant and equipment	**3 117**	2 230
– Intangible assets	**2 418**	951
Contracted	**1 512**	1 180
– Property, plant and equipment	**932**	948
– Intangible assets	**580**	232
Authorised but not contracted for	**2 221**	2 270
– Property, plant and equipment	**1 598**	1 746
– Intangible assets	**623**	524

[1] Operating cash flow per share represents cash generated from operating activities divided by the weighted number of shares in issue.
[2] Cash conversion rate represents operating cash flow per share divided by headline earnings per share.

	30 June 2024 R'million	30 June 2023 R'million
I. PAYMENT OF DEFERRED, FIXED AND CONTINGENT CONSIDERATION RELATING TO PRIOR YEAR BUSINESS TRANSACTIONS		
Disposal of Oncology portfolio in USA	**–**	38
Disposal of the European Thrombosis assets – volume incentive payments and other transaction costs[1]	**–**	(441)
Disposal of Japanese business – supply rebate payments[1]	**(117)**	(134)
Disposal of Japanese business – uninterrupted supply milestone receipt[2]	**–**	279
Other	**(41)**	(51)
	(158)	(309)
Future amounts payable for deferred, fixed and contingent consideration relating to prior year business transactions		
Japanese business	**396**	610
Non-current	**332**	465
Current	**64**	145
Other	**61**	99
Non-current	**35**	22
Current	**26**	77
	457	709
Future amounts receivable for deferred, fixed and contingent consideration relating to prior year business transactions		
Disposal of Oncology portfolio in USA	**–**	52
Current	**–**	52
J. ACQUISITION OF A PORTFOLIO OF PRODUCTS IN LATIN AMERICA		
With effect from 1 November 2023, Aspen Global Incorporated ("AGI"), a wholly owned subsidiary, acquired from Viatris Inc., the commercialisation rights and related intellectual property for a portfolio of brands in Latin America.		
Intangible assets acquired	**(5 292)**	–
Funded from operating activities	**2 063**	–
Receivables forgone	**939**	–
Liabilities and provisions raised on acquisition	**1 124**	–
	(3 229)	–

[1] *Refer to note 15 of the 30 June 2023 Annual Financial Statements for further detail. The 30 June 2023 Annual Financial Statements can be found on the Group's website https://www.aspenpharma.com/investor-relations/.*
[2] *Refer to note 7 of the 30 June 2023 Annual Financial Statements for further detail. The 30 June 2023 Annual Financial Statements can be found on the Group's website https://www.aspenpharma.com/investor-relations/.*

	Reviewed 30 June 2024 R'million
K. ACQUISITION OF A SUBSIDIARY AND BUSINESS IN CHINA NET OF CASH ACQUIRED	
Acquisition of Sandoz (China) Pharmaceutical Co., Ltd	
With effect from 1 May 2024, AGI concluded an agreement with Sandoz AG ("Sandoz"), in terms of which AGI acquired the beneficial ownership of its subsidiary, Sandoz (China) Pharmaceutical Co., Ltd. ("Sandoz China" and "the Company"), together with the commercialisation rights and related intellectual property for a portfolio of established products currently commercialised by the Company and a pipeline of products to be launched by the Company in the short to medium term. As consideration Aspen paid an upfront amount of EUR73 million and expects to pay contigent consideration based on future pipeline sales of EUR11 million. Aspen has accounted for this acquisition as a business combination in terms of IFRS 3 – *Business Combinations*.	
Due to the timing of the transaction, Aspen has not yet completed the detailed exercise to identify and value the separately identifiable intangible assets acquired and thereafter the goodwill, if any, arising as a result of the transaction. This will be completed as part of the finalisation of the accounting for the acquisition. The provisional accounting for the transaction has been as set out below.	
Fair value of assets and liabilities acquired	
Property,plant and equipment	15
Right of use assets	35
Intangible assets	1 651
Inventories	264
Receivables and other current assets	234
Deferred tax assets	120
Cash and cash equivalents	381
Borrowings	(40)
Trade and other payables	(895)
Other current and non-current financial liabilities	(185)
Onerous contract	(69)
Deferred tax liabilities	(10)
Current tax liabilities	(5)
Fair value of net assets acquired	1 496
Goodwill arising on acquisition	205
Purchase consideration	1 701
Cash and cash equivalents at acquisition	(381)
Contingent consideration	(229)
Consideration outstanding	(128)
Cash outflow on acquisition	963

The fair value of the trade receivables amounts to R191 million and it is expected that the contractual amounts can be collected.

The goodwill of R205 million comprises the value of expected synergies arising from the acquisition and other intangible assets that are not separately recognised.

The post-acquisition annual revenue is estimated to be R1,8 billion. Distinguishing the post-combination profit of Sandoz China is impracticable, given that the operations of that business will be intergrated into the Aspen Group.

L. PROCEEDS FROM DISPOSAL OF EUROPEAN ANAESTHETIC BRANDS	
With effect from 1 May 2024, AGI concluded an agreement with Sandoz, in terms of which AGI disposed to Sandoz the commercialisation rights and related intellectual property for four anaesthetic products sold by AGI in the European Economic Area for a consideration of EUR46 million.	
Proceeds	
Proceeds receivable	936
Cash inflow per statement of cash flows	936
Assets disposed	
Intangible assets	720
Liabilities raised as part of disposal	243
Loss on disposal of assets	(27)

	Note	Reviewed 30 June 2024 R'million	Audited 30 June 2023 R'million
M. IMPAIRMENT OF INTANGIBLE ASSETS			
Impairment of intangible assets can be split as follows			
GSK thrombosis business	1	**998**	369
AstraZeneca anaesthetics portfolio	1	**692**	–
GSK anaesthetics portfolio	2	**264**	433
Specialist Global brands	3	**213**	201
Project and product development costs	4	**113**	204
GSK classic brands	2	**80**	–
MSD business		**–**	58
Other		**55**	94
		2 415	1 359
Impairment of goodwill can be split as follows			
AstraZeneca anaesthetics portfolio	1	**144**	–
GSK anaesthetics portfolio		**1**	–
		145	–
Reversal of impairments can be split as follows	5		
GSK OTC brands	6	**(724)**	(206)
MSD business		**(75)**	–
Other		**(178)**	(93)
		(977)	(299)
Net impairment of intangible assets		**1 583**	1 060

The impairments have generally arisen as a result of a decline in the outlook of revenue and profitability but notable circumstances exist in the case of:
1) VBP impacts on Fraxiparine (GSK thrombosis business) and Diprivan (AstraZeneca anaesthetics portfolio).
2) Increasing competition and price inelasticity impacted three products within the GSK anaesthetics and Classic Brands portfolios.
3) A reduced sales outlook impacting three products within this portfolio.
4) Product development and other projects, which were no longer technically or commercially feasible.
5) The impairment reversals have generally arisen as a result of an improvement in the outlook for revenue and profitability.
6) Relates to a brand discontinued in Australia that is to be relaunched.

With the exception of intangible assets fully written off, the carrying value of intangible assets impaired or with impairment reversals have been determined based on either fair value less costs to sell or value-in-use calculations, using a five-year forecast horizon.

Other key assumptions used (where appropriate and in relation to the material impairments and impairment reversals) were:

	Growth in revenue (% per annum)[1]	Gross profit (% per annum)	Growth (% per annum)[2]	Pre-tax discount rate applied to cash flows (% per annum)
Impairments				
GSK thrombosis business	9	63	1	9
AstraZeneca anaesthetics portfolio	0	61	2	10
Specialist Global brands	6	58	1	11
GSK anaesthetics portfolio	1	57	2	9
GSK classic brands	(1)	72	1	8
Impairment of goodwill				
AstraZeneca anaesthetics portfolio	0	61	2	10
Impairment reversals				
GSK OTC brands	43	78	2	9
MSD business	4	66	1	11

[1] *Average compound average growth rate during the abovementioned five-year forecast.*
[2] *Average growth rate used to extrapolate cash flows beyond the abovementioned five-year forecast.*

N. ILLUSTRATIVE CONSTANT EXCHANGE RATE REPORT ON SELECTED FINANCIAL DATA

The Group has presented selected line items from the consolidated statement of comprehensive income and certain trading profit metrics on a constant exchange rate basis in the tables on the next page. The *pro forma* constant exchange rate information is presented to demonstrate the impact of fluctuations in currency exchange rates on the Group's reported results. The *pro forma* constant exchange rate information is the responsibility of the Group's Board of Directors and is presented for illustrative purposes only. Due to the nature of this information, it may not fairly present the Group's financial position, changes in equity and results of operations or cash flows. The *pro forma* constant exchange rate information has been compiled in terms of the JSE Listings Requirements and SAICA's Guide on Pro Forma Information by SAICA and the accounting policies of the Group as at 30 June 2024. The illustrative *pro forma* constant exchange rate information on selected financial data has been derived from the reviewed financial information and has been reported on by Aspen's auditor who have issued reporting accountants report thereon, which is available for inspection at the Group's registered office.

The Group's financial performance is impacted by numerous currencies which underlie the reported unaudited condensed Group financial results where, even within geographic segments, the Group trades in multiple currencies ("source currencies"). The *pro forma* constant exchange rate information has been calculated by adjusting the prior periods' reported results at the current period's reported average exchange rates. Recalculating the prior periods' numbers provides illustrative comparability with the current period's reported performance by adjusting the estimated effect of source currency movements.

The listing of average exchange rates against the Rand for the currencies contributing materially to the impact of exchange rate movements are set out below:

	June 2024 average rates	June 2023 average rates
Euro	**20,233**	18,613
Australian Dollar	**12,263**	11,948
Chinese Yuan Renminbi	**2,593**	2,555
US Dollar	**18,707**	17,758
Mexican Peso	**1,089**	0,940
Brazilian Real	**3,732**	3,455
British Pound Sterling	**23,556**	21,395
Canadian Dollar	**13,809**	13,257
Russian Ruble	**0,203**	0,260

Revenue, other income, cost of sales and expenses

For purposes of the constant exchange rate report the recalculated prior period's source currency revenue, other income, cost of sales and expenses have been recalculated from the prior period's relevant average exchange rate to the current period's relevant reported average exchange rate.

Interest paid net of investment income

Net interest paid is directly linked to the source currency of the borrowing on which it is levied and recalculated from the prior period's relevant reported average exchange rate to the current period's relevant reported average exchange rate.

Tax

The tax charge for purposes of the constant currency report has been recomputed by applying the actual effective tax rate to the recalculated profit before tax.

N. ILLUSTRATIVE CONSTANT EXCHANGE RATE REPORT ON SELECTED FINANCIAL DATA continued

	Reviewed June 2024 (at 2024 average rates) R'million	Audited June 2023 (at 2023 average rates) R'million	Change at reported exchange rates %	Recalculated Illustrative constant exchange rates June 2023 (at 2024 average rates) R'million	Change at constant exchange rates %
Key constant exchange rate indicators					
Revenue	**44 706**	40 709	10	42 660	5
Gross profit	**19 454**	18 934	3	19 688	(1)
Operating profit	**6 998**	7 822	(11)	8 073	(13)
Adjusted for					
– Depreciation	**1 390**	1 247		1 305	
– Amortisation	**583**	541		571	
– Loss on sale of assets	**34**	1		2	
– Net impairment of assets	**1 667**	1 064		1 143	
– Restructuring costs	**227**	278		302	
– Transaction costs	**356**	190		199	
– Insurance compensation on assets	**–**	(43)		(44)	
Normalised EBITDA[1]	**11 255**	11 100	1	11 551	(3)
Normalised headline earnings	**6 628**	6 657	(0)	6 928	(4)
Basic and diluted earnings per share (cents)	**991,4**	*1 176,9*	*(16)*	*1 212,4*	*(18)*
Headline and diluted headline earnings per share (cents)	**1 356,6**	*1 405,4*	*(3)*	*1 458,3*	*(7)*
Normalised headline and diluted headline earnings per share (cents)	**1 492,1**	*1 498,5*	*(0)*	*1 559,6*	*(4)*

[1] *Normalised EBITDA represents operating profit before depreciation and amortisation adjusted for specific non-trading items as defined in the Group's accounting policy.*

	Reviewed June 2024 (at 2024 average rates) %	Reviewed June 2023 (at 2023 average rates) %
Revenue currency mix		
Euro	**34**	30
South African Rand	**15**	15
Australian Dollar	**14**	15
Chinese Yuan Renminbi	**5**	9
US Dollar	**6**	8
Mexican Peso	**5**	4
Brazilian Real	**5**	4
British Pound Sterling	**2**	1
Canadian Dollar	**2**	2
Russian Ruble	**1**	1
Other currencies	**11**	11
Total	**100**	100

GROUP SUPPLEMENTARY INFORMATION continued

NOTES continued

N. ILLUSTRATIVE CONSTANT EXCHANGE RATE REPORT ON SELECTED FINANCIAL DATA continued

Group segmental analysis

Reviewed June 2024 (at 2024 average rates)

	Prescription R'million	OTC R'million	Injectables R'million	Total Commercial Pharmaceuticals R'million	Manufacturing R'million	Total R'million
Revenue	**11 380**	**9 706**	**9 484**	**30 570**	**14 136**	**44 706**
Cost of sales	**(4 447)**	**(4 012)**	**(3 964)**	**(12 423)**	**(12 829)**	**(25 252)**
Gross profit	**6 933**	**5 694**	**5 520**	**18 147**	**1 307**	**19 454**
Selling and distribution expenses						**(6 481)**
Administrative expenses						**(3 657)**
Net other operating income						**549**
Depreciation						**1 390**
Normalised EBITDA[1]						**11 255**
Gross profit %	**60,9**	**58,7**	**58,2**	**59,4**	**9,2**	**43,5**
Selling and distribution expenses %						**14,5**
Administrative expenses %						**8,2**
Normalised EBITDA %						**25,2**

Recalculated illustrative constant exchange rate June 2023 (at 2024 average rates)[2]

	Prescription R'million	OTC R'million	Injectables R'million	Total Commercial Pharmaceuticals R'million	Manufacturing R'million	Total R'million
Revenue	10 286	9 388	10 796	30 470	12 190	42 660
Cost of sales	(4 022)	(3 921)	(4 354)	(12 297)	(10 675)	(22 972)
Gross profit	6 264	5 467	6 442	18 173	1 515	19 688
Selling and distribution expenses						(6 009)
Administrative expenses						(3 754)
Net other operating income						321
Depreciation						1 305
Normalised EBITDA[1]						11 551
Gross profit %	60,9	58,2	59,7	59,6	12,4	46,2
Selling and distribution expenses %						14,1
Administrative expenses %						8,8
Normalised EBITDA %						27,1

Change

	Prescription %	OTC %	Injectables %	Total Commercial Pharmaceuticals %	Manufacturing %	Total %
Revenue	11	3	(12)	0	16	5
Cost of sales	11	2	(9)	1	20	10
Gross profit	11	4	(14)	0	(14)	(1)
Selling and distribution expenses						8
Administrative expenses						(3)
Net other operating income						71
Depreciation						7
Normalised EBITDA[1]						(3)

[1] *Normalised EBITDA represents operating profit before depreciation and amortisation adjusted for specific non-trading items as defined in the Group's accounting policy.*

[2] *Refer to Basis of Accounting for restatement as a result of segmental classifications.*

N. ILLUSTRATIVE CONSTANT EXCHANGE RATE REPORT ON SELECTED FINANCIAL DATA continued

Group revenue segmental analysis

for the year ended 30 June	**Reviewed June 2024 (at 2024 average rates) R'million**	Recalculated illustrative constant exchange rate June 2023 (at 2024 average rates)[1] R'million	Change %
COMMERCIAL PHARMACEUTICALS BY CUSTOMER GEOGRAPHY	**30 570**	30 470	0
Africa Middle East	**9 021**	8 148	11
Americas	**6 677**	5 564	20
Australasia	**5 904**	5 987	(1)
Europe CIS	**4 868**	5 148	(5)
Asia	**4 100**	5 623	(27)
MANUFACTURING BY GEOGRAPHY OF MANUFACTURE			
Finished dose form	**5 262**	4 257	24
Europe CIS	**4 131**	2 885	43
Australasia	**781**	746	5
Africa Middle East	**216**	484	(55)
Asia	**100**	122	(18)
Americas	**34**	20	70
Active pharmaceutical ingredients	**5 102**	5 430	(6)
Europe CIS	**4 832**	5 231	(8)
Africa Middle East	**270**	199	36
Heparin	**3 772**	2 503	51
Europe CIS	**3 772**	2 503	51
Total Manufacturing revenue	**14 136**	12 190	16
TOTAL REVENUE	**44 706**	42 660	5
SUMMARY OF REGIONS			
Europe CIS	**17 603**	15 767	12
Africa Middle East	**9 507**	8 831	8
Americas	**6 711**	5 584	20
Australasia	**6 685**	6 733	(1)
Asia	**4 200**	5 745	(27)
TOTAL REVENUE	**44 706**	42 660	5

[1] *Refer to Basis of Accounting for restatement as a result of segmental classifications.*

N. ILLUSTRATIVE CONSTANT EXCHANGE RATE REPORT ON SELECTED FINANCIAL DATA continued

Commercial Pharmaceuticals therapeutic area analysis

	Reviewed June 2024 (at 2024 average rates)			
	Prescriptions R'million	OTC R'million	Injectables R'million	Total R'million
BY CUSTOMER GEOGRAPHY				
Africa Middle East	**4 242**	**3 561**	**1 218**	**9 021**
Americas	**2 832**	**1 450**	**2 395**	**6 677**
Australasia	**2 618**	**2 430**	**856**	**5 904**
Europe CIS	**991**	**1 974**	**1 903**	**4 868**
Asia	**697**	**291**	**3 112**	**4 100**
Total Commercial Pharmaceuticals	**11 380**	**9 706**	**9 484**	**30 570**

	Recalculated illustrative constant exchange rate June 2023 (at 2024 average rates)[1]			
	Prescriptions R'million	OTC R'million	Injectables R'million	Total R'million
BY CUSTOMER GEOGRAPHY				
Africa Middle East	3 881	3 496	771	8 148
Americas	1 990	1 441	2 133	5 564
Australasia	2 788	2 340	859	5 987
Europe CIS	1 067	1 838	2 243	5 148
Asia	560	273	4 790	5 623
Total Commercial Pharmaceuticals	10 286	9 388	10 796	30 470

	Change			
	Prescriptions %	OTC %	Injectables %	Total %
BY CUSTOMER GEOGRAPHY				
Africa Middle East	9	2	58	11
Americas	42	1	12	20
Australasia	(6)	4	0	(1)
Europe CIS	(7)	7	(15)	(5)
Asia	24	7	(35)	(27)
Total Commercial Pharmaceuticals	11	3	(12)	0

[1] *Refer to Basis of Accounting for restatement as a result of segmental classifications.*

O. BASIS OF ACCOUNTING

The Group financial results contained in the condensed report are prepared in accordance with the requirements of the JSE Limited Listings Requirements for condensed reports and the requirements of the Companies Act of South Africa. The Listings Requirements require condensed reports to be prepared in accordance with the framework concepts and the measurement and recognition requirements of IFRS Accounting Standards and the SAICA Financial Reporting Guides as issued by the Accounting Practices Committee and Financial Pronouncements as issued by the Financial Reporting Standards Council and to also, as a minimum, contain the information required by IAS 34 – *Interim Reporting*.

The accounting policies applied in the preparation of these condensed Group financial results are in terms of IFRS and are consistent with those used in the annual financial statements for the year ended 30 June 2023 except for changes to the segmental analysis as well as additional accounting policies.

These condensed Group financial results have been prepared under the supervision of the Group Chief Financial Officer, SM Capazorio CA(SA) and approved by the Board of Directors.

Restatement of the Group segmental analysis

The Group has revised and refined its reportable segments to reflect the updated operating model which supports the Group's strategy for its Commercial Pharmaceuticals and Manufacturing businesses and aligns to the way in which the business is managed and reported on by the Chief Operating Decision Maker. The full year comparatives have been restated to ensure analytical comparability.

Commercial Pharmaceuticals

The Commercial Pharmaceuticals business segments were previously called Sterile Focus Brands and Regional Brands. In the current year the updated business segments are set out below:

- Injectables – Sterile products in injectable form primarily administered in hospitals and also those prescribed and administered by either physicians or in a retail pharmacy environment. Principle therapeutic areas covered are anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines. Key brands include Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon and Xylocaine (Injectables)
- Over-the-counter ("OTC") – Products that do not require prescription and are primarily sold in the retail pharmacy and Fast-Moving Consumer Goods sectors, where brand recognition, marketing and communication with pharmacists are influential in consumers' product choices. Key brands include Emla, Maltofer, Ovestin, Solpadeine and Xylocaine (Topicals).
- Prescription – All other products which generally require a prescription from a healthcare professional. Primary therapeutic areas are anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids. Key brands include Eltroxin, Imuran, Lipitor, Lyrica and Zyloric.

Manufacturing

The Finished Dose Form segment was previously FDF Sterile and FDF Other. In the current year, the updated business segments are set out below:

- Active Pharmaceutical Ingredients ("API") – All API sales excluding Heparin-based APIs.
- Finished Dose Form ("FDF") – FDF products manufactured for third parties.
- Heparin – Heparin-based API sales to third parties, including, where applicable, the Heparin-based API portion of FDF sales.

SUBSEQUENT EVENTS

- Dividends

Subsequent to year-end, the Board has declared a gross dividend, which will be paid from income reserves of 359 cents per ordinary share (2023: 342 cents per ordinary share) to shareholders recorded in the share register of the Company at the close of business on 20 September 2024 (2023: Declared on 29 August 2023 and paid 26 September 2023). In compliance with IAS 10 – *Events After Balance Sheet Date*, the dividend will be accounted for in the financial statements in the year ending 30 June 2025.

- New Development Finance Institutions ("DFI") Loan

During August 2024, the Group secured an additional EUR500 million seven-year amortising term loan (the "New DFI Loan") from a club of development finance institutions. The New DFI Loan is expected to become effective and be disbursed during September 2024. The proceeds of the New DFI Loan will be used by the Group to repay existing loan facilities and to fund expansionary capital expenditure. The commercial terms, covenants and undertakings of the New DFI Loan are materially similar to the Group's existing EUR debt facilities.

REVIEW CONCLUSION

These reviewed condensed Group financial results for the year ended 30 June 2024 have been reviewed by the independent external auditor, Ernst & Young Inc. and their unmodified review report is available for inspection at the Group's registered office. The review was performed in accordance with ISRE 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity'. Any reference to future financial performance included in this announcement has not been reviewed or reported on by the Group's external auditor. The auditor's report does not necessarily report on all of the information contained in this announcement/financial results. Shareholders are therefore advised that in order to obtain a full understanding of the nature of the auditor's engagement, they should obtain a copy of the auditor's report together with the accompanying financial information from the Group's registered office.

Normalised headline earnings, normalised headline earnings per share, normalised EBITDA, and Constant Exchange Rate reporting in Note N are considered to be pro forma financial information in terms of the JSE Listings Requirements. These measures have been prepared to show the Group's preferred internal key financial metrics. Accordingly, it has been prepared for illustrative purposes only and because of its nature may not fairly present the Group's financial position, changes in equity, results of operations or cash flows. The pro forma financial information is the responsibility of the directors and the Group's auditor, Ernst & Young Inc., have issued an independent auditor's report on the compilation thereof, which is available for inspection at the Group's registered offices.

The Directors

Aspen Pharmacare Holdings Limited
Aspen Place
9 Rydall Vale Park
Douglas Saunders Drive
La Lucia Ridge
Durban

Independent auditor's review report on the Reviewed Condensed Group Financial Results for the year ended 30 June 2024

We have reviewed the Reviewed Condensed Group Financial Results of Aspen Pharmacare Holdings Limited and its subsidiaries contained in the accompanying report, which comprise the accompanying Condensed Group statement of financial position as at 30 June 2024, Group statement of comprehensive income, Group statement of changes in equity, and Group statement of cash flows for the year then ended, and selected explanatory notes, excluding Note N.

Directors' Responsibility for the Reviewed Condensed Group Financial Results

The directors are responsible for the preparation and presentation of these Reviewed Condensed Group Financial Results in accordance with the International Financial Reporting Standards (IFRS), IAS 34 Interim Financial Reporting, as issued by the International Accounting Standards Board (IASB); the SAICA Financial Reporting Guides, as issued by the Accounting Practices Committee; Financial Reporting Pronouncements as issued by the Financial Reporting Standards Council; the requirements of the Companies Act of South Africa; the JSE Listing Requirements and for such internal control as the directors determine is necessary to enable the preparation of Reviewed Condensed Group Financial Results that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on these Reviewed Condensed Group Financial Results based on our review. We conducted our review in accordance with International Standard on Review Engagements (ISRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity.' This standard requires us to conclude whether anything has come to our attention that causes us to believe that the Reviewed Condensed Group Financial Results are not prepared in all material respects in accordance with the applicable financial reporting framework. This standard also requires us to comply with relevant ethical requirements.

A review of Reviewed Condensed Group Financial Results in accordance with ISRE 2410 is a limited assurance engagement. We perform procedures, primarily consisting of making enquiries of management and others within the entity, as appropriate, and applying analytical procedures, and evaluating the evidence obtained. The procedures performed in a review are substantially less than and differ in nature from those performed in an audit conducted in accordance with International Standards on Auditing. Accordingly, we do not express an audit opinion on these Reviewed Condensed Group Financial Results.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Reviewed Condensed Group Financial Results, which comprise the accompanying Reviewed Condensed Group statement of financial position as at 30 June 2024, Group statement of comprehensive income, Group statement of changes in equity and Group statement of cash flows for the year then ended, and selected explanatory notes, of Aspen Pharmacare Holdings Limited and its subsidiaries for year ended 30 June 2024 are not prepared, in all material respects, in accordance with the International Financial Reporting Standard, (IAS) 34 Interim Financial Reporting as issued by the International Accounting Standards Board (IASB), the SAICA Financial Reporting Guides, as issued by the Accounting Practices Committee, Financial Reporting Pronouncements as issued by the Financial Reporting Standards Council, the requirements of the Companies Act of South Africa and the JSE Listing Requirements.

DocuSigned by:
Ernst & Young Inc
DEC2A8455D8C4FA...

Ernst & Young Inc.
Derek Engelbrecht
Director
Registered Auditor
Chartered Accountant (South Africa)

3 September 2024

DIRECTORS
KD Dlamini* (Chair), SM Capazorio, L de Beer*, N Dongwana*, RT Haman, BJ Kruger*, TM Mkhwanazi*, CN Mortimer*, YG Muthien*, DS Redfern*, SB Saad
** Non-executive director*

COMPANY SECRETARY
R Khan

REGISTERED OFFICE
Building Number 8, Healthcare Park, Woodlands Drive, Woodmead
PO Box 1587, Gallo Manor, 2052
Telephone +27 11 239 6100
Telefax +27 11 239 6144

SPONSOR
Investec Bank Limited

TRANSFER SECRETARY
JSE Investor Services (Pty) Limited
13th Floor, 19 Ameshoff Street, Braamfontein, 2001
PO Box 4844, Johannesburg, 2000

www.aspenpharma.com

Disclaimer
We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “prospects”, “believe”, “anticipate”, “expect”, “intend”, “seek”, “will”, “plan”, “indicate”, “could”, “may”, “endeavour” and “project” and similar expressions are intended to identify such forward looking statements, but are not the exclusive means of identifying such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that predictions, forecasts, projections and other forward-looking statements will not be achieved. If one or more of these risks materialise, or should underlying assumptions prove incorrect, actual results may be very different from those anticipated. The factors that could cause our actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements are discussed in each year’s annual report. Forward-looking statements apply only as of the date on which they are made, and we do not undertake other than in terms of the Listings Requirements of the JSE Limited, any obligation to update or revise any of them, whether as a result of new information, future events or otherwise. Any profit forecasts published in this report are unaudited and have not been reviewed or reported on by Aspen’s external auditors.